← Patent-cliff monitor small molecule LUMRYZ SODIUM OXYBATE
Loss of exclusivity March 2042 latest FDA-listed patent expiry
Company ALKERMES INC
Drug detail Brand name LUMRYZ Active ingredient SODIUM OXYBATE Strength 7.5GM/PACKET Dosage form FOR SUSPENSION, EXTENDED RELEASE Route ORAL Modality Small molecule FDA approval May 2023 Marketing status RX
Listed patents Patent Expires Type 11779557 March 2042 use U-3705 11583510 February 2042 use U-3578 11602512 July 2037 use U-3577 11400065 July 2037 use U-3579 11000498 July 2037 product 12128021 July 2037 use U-4022 11986451 July 2037 use U-3934 10952986 July 2037 use U-3601 12097176 July 2037 use U-4006 12109186 July 2037 product 12115143 July 2037 product 11896572 July 2037 product 10272062 July 2037 product 12115142 July 2037 product 11839597 July 2037 product 12138239 July 2037 product 11504347 July 2037 product 12115145 July 2037 product 12097175 July 2037 product 10973795 July 2037 product 11065224 July 2037 product 11052061 July 2037 product 12115144 July 2037 product 11766418 July 2037 product 10736866 July 2037 product 12303478 July 2037 use U-4189 12144793 July 2037 product 11602513 July 2037 use U-3576
Regulatory exclusivity Code Expires ODE-494 October 2031 ODE-431 May 2030 NP May 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.